{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(4)"],"submitter":["Ramaswamy A"],"funding":["Nag Foundation Grant to the institute","TMC Research Administrative Council (TRAC) Tata Memorial Centre"],"pubmed_abstract":["<h4>Background</h4>We evaluated whether the addition of docetaxel (D) to a combination comprising 5-fluorouracil/leucovorin (5-FU/LV) or capecitabine (C) plus oxaliplatin (O) (DOF/DOX) improved overall survival (OS) compared with 6 months of 5-fluorouracil (5-FU) or capecitabine in combination with oxaliplatin (FOLFOX/CAPOX) alone in advanced HER2-negative gastroesophageal junction and gastric adenocarcinomas (G/GEJ).<h4>Methods</h4>This study was an investigator-initiated, open-label, multi-institutional, randomized phase III trial in adult patients with HER2-negative advanced G/GEJs. The primary endpoint of the study was a comparison of median OS by Kaplan-Meier method. Next-generation sequencing was performed on tissue.<h4>Results</h4>Of the 324 patients randomly assigned between July 2"],"journal":["JNCI cancer spectrum"],"pagination":["pkae054"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11316615"],"repository":["biostudies-literature"],"pubmed_title":["Docetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancers."],"pmcid":["PMC11316615"],"pubmed_authors":["Singh SN","Ankathi SK","Dhal I","Gupta A","Desai V","Noronha V","Patil R","Ramaswamy A","Patel S","Menon N","Kapoor A","Prabhash K","Srinivas S","Jadhav P","Mishra BK","Dubashi B","Shetty O","Pal V","Nashikkar C","Parulekar M","Bhargava P","Syed N","Singh A","Ganesan P","Joshi A","Suganiya R","Kayal S","Ananthakrishnan R","Kaushal RK","Sansar B","Kannan S","Chaugule D","Patil VM","Mandavkar S","Shah A","Srinivasan ND","Kapu V","Vinayak KR","Samaddar D","Kaaviya D","Ostwal V"],"additional_accession":[]},"is_claimable":false,"name":"Docetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancers.","description":"<h4>Background</h4>We evaluated whether the addition of docetaxel (D) to a combination comprising 5-fluorouracil/leucovorin (5-FU/LV) or capecitabine (C) plus oxaliplatin (O) (DOF/DOX) improved overall survival (OS) compared with 6 months of 5-fluorouracil (5-FU) or capecitabine in combination with oxaliplatin (FOLFOX/CAPOX) alone in advanced HER2-negative gastroesophageal junction and gastric adenocarcinomas (G/GEJ).<h4>Methods</h4>This study was an investigator-initiated, open-label, multi-institutional, randomized phase III trial in adult patients with HER2-negative advanced G/GEJs. The primary endpoint of the study was a comparison of median OS by Kaplan-Meier method. Next-generation sequencing was performed on tissue.<h4>Results</h4>Of the 324 patients randomly assigned between July 2","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2025-04-22T14:46:51.404Z","creation":"2025-04-06T01:11:07.117Z"},"accession":"S-EPMC11316615","cross_references":{"pubmed":["39067037"],"doi":["10.1093/jncics/pkae054"]}}